Outlook Therapeutics (OTLK) Enterprise Value (2015 - 2026)
Outlook Therapeutics (OTLK) reported Enterprise Value of -$7.7 million for Q1 2026, down 2.54% year-over-year from -$8.0 million in Q1 2025, and up 10.71% quarter-over-quarter from -$8.7 million in Q4 2025.
Outlook Therapeutics (OTLK) Enterprise Value (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Enterprise Value data on file, last reported at -$7.7 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$7.7 million, down 2.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.7 million (down 2.54% YoY), and the FY2025 annual result was -$8.1 million, up 45.85% from the prior year.
- Enterprise Value advanced to -$7.7 million in Q1 2026 per OTLK's latest filing, from -$8.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$5.7 million in Q4 2024 and troughed at -$58.4 million in Q1 2022.
- A 5-year average of -$23.9 million and a median of -$17.4 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value tumbled 57.19% in 2022, then soared 84.0% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$52.3 million in 2022, then surged by 80.21% to -$10.4 million in 2023, then soared by 44.94% to -$5.7 million in 2024, then slumped by 52.17% to -$8.7 million in 2025, then rose by 10.71% to -$7.7 million in 2026.
- Business Quant data shows OTLK's Enterprise Value at -$7.7 million in Q1 2026, -$8.7 million in Q4 2025, and -$8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -584.73 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | -7.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.75 Mn |
| Dec 31, 2025 | -8.68 Mn |
| Sep 30, 2025 | -8.08 Mn |
| Jun 30, 2025 | -8.90 Mn |
| Mar 31, 2025 | -7.56 Mn |
| Dec 31, 2024 | -5.70 Mn |
| Sep 30, 2024 | -14.93 Mn |
| Jun 30, 2024 | -32.02 Mn |
| Mar 31, 2024 | -47.23 Mn |
| Dec 31, 2023 | -10.36 Mn |
| Sep 30, 2023 | -23.39 Mn |
| Jun 30, 2023 | -33.71 Mn |
| Mar 31, 2023 | -43.63 Mn |
| Dec 31, 2022 | -52.34 Mn |
| Sep 30, 2022 | -17.40 Mn |
| Jun 30, 2022 | -26.02 Mn |
| Mar 31, 2022 | -58.42 Mn |
| Dec 31, 2021 | -70.15 Mn |
| Sep 30, 2021 | -14.48 Mn |
| Jun 30, 2021 | -19.69 Mn |